{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-I57ZUEUH/8f584a97-e398-47da-9acc-88ae5d564e0e/HTML","dcterms:extent":"25 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-I57ZUEUH/58b02d7d-7905-4e6f-bd43-438623e9340d/PDF","dcterms:extent":"82 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-I57ZUEUH/04ca5034-8662-4707-abe6-3feb87d8a526/TEXT","dcterms:extent":"22 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-I57ZUEUH","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"2003","dc:creator":"Veingerl, Bojan","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:37"},{"@xml:lang":"sl","#text":"6 strani"},{"@xml:lang":"sl","#text":"str. 73-78"}],"dc:identifier":["ISSN:1318-2099","COBISSID:16558041","URN:URN:NBN:SI:doc-I57ZUEUH"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Association of Radiology and Oncology"},"dc:subject":[{"@xml:lang":"en","#text":"Blood"},{"@xml:lang":"en","#text":"Carcinoembryonic Antigen"},{"@xml:lang":"en","#text":"Colorectal Neoplasms"},{"@xml:lang":"sl","#text":"črevesje"},{"@xml:lang":"sl","#text":"črevesne bolezni"},{"@xml:lang":"en","#text":"diagnostika"},{"@xml:lang":"en","#text":"Follow-Up Studies"},{"@xml:lang":"en","#text":"Genetics"},{"@xml:lang":"sl","#text":"Karcinoembrionalni antigen"},{"@xml:lang":"sl","#text":"Kolorektalne novotvorbe"},{"@xml:lang":"en","#text":"Prognosis"},{"@xml:lang":"sl","#text":"Prognoza"},{"@xml:lang":"sl","#text":"rak (medicina)"},{"@xml:lang":"sl","#text":"Sledilne študije"},{"@xml:lang":"en","#text":"Surgery"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Early postoperative serum carcinoembryonic antigen levels in patients operated for colorectal carcinoma| a new method for following-up|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. The only method of treatment offering a favourable prognosis for colorectal carcinoma is radical resection of the part of the colon or rectum including the pertaining lymph nodes and eventual radical removal of metastases. But even such presumably curative surgery does not warrant full recovery of all operated patients as recurrences are frequent and according tomost analyses 5-year survival is lower than 50%. Therefore, additional treatment is attempted in some patients. Various prognostic factor of disease recurrance are helful. One such prognostic sign is serum carcinoembryonic antigen (CEA) level measured soon after surgery. Conclusions. All patients with radical R0 resection, according to their postoperative serum CEA levels and the CEA half-life fall into three groups: CEA R0, CEA R1, and CEA R2 resected patients. A statistically significant difference regarding survival and number of recurrence was noted among patients categorized bz the stage of disease, particularly between the three groups of patients and the group having been undergone presumably curative surgery"},{"@xml:lang":"sl","#text":"Izhodišča. Pri bolnikih z rakom debelega črevesa in danke le kirurško zdravljenje omogoča njihovo ugodnejšo prognozo. Potrebno je narediti radikalnoresekcijo zajetega debelega črevesa ali danke ter odstraniti pripadajoče limfne bezgavke in morebitne metastatske spremembe. Kljub radikalnemu kirurškemu posegu, ki bi naj bil domnevno ozdravilen, pa takšno zdravljenje ne zagotavlja popolne ozdravitve. Pogosta je ponovitev bolezni in kakor kažejo različne analize, je 5-letno preživetje manjše kot 50%. Tako je pri veliko bolnikih potrebno dodatno zdravljenje. Pri tem nam pomagajo različni napovedni dejavniki, med njimi tudi nivo karcinoembrionalnega antigena (CEA) v serumu, ki ga določimo takoj po operaciji. Zaključki. Vse bolnike, pri katerih je bila narejena radikalna RO resekcija, lahko glede na vrsto resekcije in na njihov pooperativni nivo serumskega CEA (ob upoštevanju razpolovne življenjske dobe CEA) razdelimo v 3 skupine: cEARO, CEAR1 in CEAR2.Ob upoštevanju stadija bolezni smo med temi skupinami ugotovili statistično značilno razliko v preživetju in pogostnosti ponovitve bolezni. Razlika je bila najbolj očitna pri bolnikih, pri katerih je bil kirurški posegdomnevno ozdravilen"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-I57ZUEUH","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-I57ZUEUH"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-I57ZUEUH/58b02d7d-7905-4e6f-bd43-438623e9340d/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo radiologije in onkologije"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-I57ZUEUH/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-I57ZUEUH"}}}}